Author

D. H. Raulet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

C. Blaj· 1 shared C. J. Nicolai· 1 shared C. O. Ndubaku· 1 shared F. J. van Kuppeveld· 1 shared G. Snyder· 1 shared J. E. Ver Eecke· 1 shared J. J. Woodward· 1 shared K. C. Garcia· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. Blaj

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

STING activation depends on ACBD3 and other phosphatidylinositol 4-phosphate-regulating proteins

R. D. Luteijn, S. R. van Terwisga, J. E. Ver Eecke, L. Onia, S. A. Zaver, J. J. Woodward, D. H. Raulet, F. J. van Kuppeveld

This study identifies ACBD3 and PI4P-regulating proteins as essential for STING activation and shows that modulating PI4P levels can enhance STING signaling and cytokine production.

bioRxiv · Oct 17, 2022 · PreprintImmunology

Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors

N. K. Wolf, C. Blaj, L. Picton, G. Snyder, L. Zhang, C. J. Nicolai, C. O. Ndubaku, S. M. McWhirter, K. C. Garcia, D. H. Raulet

The paper combines a STING agonist and an IL-2 superkine to enhance cancer immunotherapy, showing efficacy against both MHC I-deficient and MHC I+ tumors.

bioRxiv · Nov 2, 2021 · PreprintImmunology